Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of PT199 Administered Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors, including Pancreatic Cancer

Summary

The purpose of this phase I study is to evaluate the safety and tolerability of PT199 alone and in combination with Anti-PD-1 monoclonal antibody in patients with locally advanced and metastatic solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05431270
Study ID: PT199X1101
Trial Phase: Phase I

Trial Sponsor: Phanes Therapeutics
Therapies Used in This Trial: Tislelizumab, PT199

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search